All In MedTech

FDA Clearance Tracker · P000058-S059

INFUSE(R) BONE GRAFT

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 4, 2015 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 4, 2015

Approved

Time to decision

235 days

Received Apr 13, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P000058-S059
Device name
INFUSE(R) BONE GRAFT
Applicant location
Memphis, TN
Received
Apr 13, 2015
Decided
Dec 4, 2015
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P000058

Device type

Device class
Class III

Every decision under product code NEK

FDA's approval statement

As written in FDA's record.

APPROVAL FOR EXPANSION OF THE APPROVED INDICATIONS FOR USE OF INFUSE BONE GRAFT TO INCLUDE IMPLANTATION WITH TWO ADDITIONAL INTERBODY FUSION DEVICES, THE PERIMETER INTERBODY FUSION DEVICE OR THE CLYDESDALE SPINAL SYSTEM, UTILIZING SELECT OPEN SURGICAL PROCEDURES IN CONJUNCTION WITH SUPPLEMENTAL SPINAL FIXATION HARDWARE. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME INFUSE BONE GRAFT/ MEDTRONIC INTERBODY FUSION DEVICE AND IS INDICATED FOR:SPINAL FUSION PROCEDURES IN SKELETALLY MATURE PATIENTS WITH DEGENERATIVE DISC DISEASE (DDD) AT ONE LEVEL FROM L2-S1. DDD IS DEFINED AS DISCOGENIC BACK PAIN WITH DEGENERATION OF THE DISC CONFIRMED BY PATIENT HISTORY AND RADIOGRAPHIC STUDIES. THESE DDD PATIENTS MAY ALSO HAVE UP TO GRADE I SPONDYLOLISTHESIS OR GRADE 1 RETROLISTHESIS AT THE INVOLVED LEVEL. PATIENTS RECEIVING THE INFUSE BONE GRAFT/MEDTRONIC INTERBODY FUSION DEVICE SHOULD HAVE HAD AT LEAST SIX MONTHS OF NONOPERATIVE TREATMENT PRIOR TO TREATMENT WITH THE INFUSE BONE GRAFT/MEDTRONIC INTERBODY FUSION DEVICE. THE FOLLOWING INTERBODY DEVICES AND SURGICAL APPROACHES MAY BE USED WITH INFUSE BONE GRAFT:1) THE LT-CAGE LUMBAR TAPERED FUSION DEVICE, IMPLANTED VIA AN ANTERIOR OPEN OR AN ANTERIOR LAPAROSCOPIC APPROACH AT A SINGLE LEVEL; 2) THE INTER FIX OR INTER FIX RP THREADED FUSION DEVICE, IMPLANTED VIA AN ANTERIOR OPEN APPROACH AT A SINGLE LEVEL; 3) THE PERIMETER INTERBODY FUSION DEVICE IMPLANTED VIA A RETROPERITONEAL ANTERIOR LUMBAR INTERBODY FUSION (ALIF) AT A SINGLE LEVEL FROM L2-S1OR AN OBLIQUE LATERAL INTERBODY FUSION (OLIF) APPROACH AT A SINGLE LEVEL FROM L5-S1; AND 4) THE CLYDESDALE SPINAL SYSTEM, IMPLANTED VIA AN OLIF APPROACH AT A SINGLE LEVEL FROM L2-L5.¿

Source documents

Other decisions for Medtronic Sofamor Danek USA, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.